These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20687887)

  • 41. [The side effects of antiretroviral therapy].
    Hartmann M
    Hautarzt; 2006 Nov; 57(11):969-74. PubMed ID: 17036249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic complications of HIV therapy in children.
    McComsey GA; Leonard E
    AIDS; 2004 Sep; 18(13):1753-68. PubMed ID: 15316336
    [No Abstract]   [Full Text] [Related]  

  • 44. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.
    Addy CL; Gavrila A; Tsiodras S; Brodovicz K; Karchmer AW; Mantzoros CS
    J Clin Endocrinol Metab; 2003 Feb; 88(2):627-36. PubMed ID: 12574192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic and hepatobiliary side effects of antiretroviral therapy (ART).
    Lugassy DM; Farmer BM; Nelson LS
    Emerg Med Clin North Am; 2010 May; 28(2):409-19, Table of Contents. PubMed ID: 20413022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
    Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM
    Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dyslipidemia related to antiretroviral therapy.
    Estrada V; Portilla J
    AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.
    Chen D; Misra A; Garg A
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE; Telenti A
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiretroviral therapy: are we aware of adverse effects?
    Wig N
    J Assoc Physicians India; 2002 Sep; 50():1163-71. PubMed ID: 12516702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA; Bryant BJ;
    Am J Pharmacogenomics; 2004; 4(3):141-50. PubMed ID: 15174895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disorders of body fat distribution in HIV-1-infected patients.
    Moreno S; Miralles C; Negredo E; Domingo P; Estrada V; Gutiérrez F; Lozano F; Martínez E
    AIDS Rev; 2009; 11(3):126-34. PubMed ID: 19654854
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents.
    Fortuny C; Deyà-Martínez Á; Chiappini E; Galli L; de Martino M; Noguera-Julian A
    Pediatr Infect Dis J; 2015 May; 34(5 Suppl 1):S36-43. PubMed ID: 25629891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy.
    Bonnet E; Genoux A; Bernard J; Fauvel J; Massip P; Perret B
    Clin Chem Lab Med; 2007; 45(7):815-21. PubMed ID: 17617020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 60. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.